日韩A∨无码成人精品国产,激情A片久久久久久久,无码天堂va亚洲va在线va免费无码又爽又刺激高潮虎虎视频,伊人无码精品久久一区二区,婷婷激情五月一区二区三区播放中美女 赤裸 一区二区三区,精品亚洲成A人片在线观看少妇,亚洲欧美综合国产不卡,国产精品亚洲а∨天堂免

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Universal Cell Platform


Universal Cell Platform (TyUCell?) refers to the use of gene editing technology to transform allogeneic immune cells to eliminate immune rejection. On the basis of ensuring the safety and effectiveness of cell products, it realizes the generalization of immune cell therapy products. Tyucell cell products have the advantages of low cost, wide application range, short production cycle, stable preparation process and good therapeutic effect. The platform can be used for clinical treatment after a large number of expansion of cells from healthy donors. At the same time, it can realize the large-scale and batch production of cell products, significantly reduce the production cost, shorten the waiting time of patients, and provide modern cell therapy products that meet the urgent needs of clinic.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
亚洲欧美日韩中文字幕在线国产成人高清亚洲亚洲日本人成网站| 日本人成在线播放免费课体台| 久久久久久国产精品免费免| 99久高清在线观看视频| 免费人成再在线观看网站| 乱人伦精品视频在线观看| 日韩日本系列有码字幕中文字幕| 重口SM一区二区三区视频| 中文字幕人成乱码中文乱码| 国产高清狼人香蕉在线| 动漫精品啪啪一区二区三区| 女人站着被舌头伺候| 日本一区二区三区不卡免费| 国产毛片一区亚洲s色大片| 国产精品无码一区二区三区不卡| 少妇AV射精精品蜜桃专区| 亚洲日韩国产AV无码无码精品| 日韩女同中文字幕永久在线| 噜噜噜噜私人影院| 欧美亚洲综合在线观看| 多人性激烈的欧美三级视频| 9889 精品国产一区二区三区香蕉| 女人五月天激情四射AV| 国产精品亚洲А∨无码播放不卡| 最新国产精品拍自在线播放| 日韩专区一中文字目一区二区| 亚洲不卡av不卡一区二区| 日韩精品一区二区三区视频在线观看| 国产野战无套av毛片| 亚洲专区一区二区在线观看| 91综合高清自在线看| 亚洲AV综合伊人AV一区加勒比| 欧美疯狂做受XXXXX高潮| 18禁无遮挡啪啪无码网站| 国色天香在线视频观看播放| 国产真实videos灌满| 日韩一区二三区国产好的精华| 亚洲欧美一级久久精品| 无码专区精品在线播放| 两根大肉大捧一进一出好爽视频| 中文字幕不卡在线观看|